Literature DB >> 30869664

Bifunctional magnetopolymersomes of iron oxide nanoparticles and carboxymethylcellulose conjugated with doxorubicin for hyperthermo-chemotherapy of brain cancer cells.

Sandhra M Carvalho1, Alice G Leonel, Alexandra A P Mansur, Isadora C Carvalho, Klaus Krambrock, Herman S Mansur.   

Abstract

Glioblastoma is the most aggressive primary brain cancer, which has no cure yet. Emerging nanotheranostic alternatives such as magnetic iron oxide nanoparticles (MIONs) have great potential as multimodal cancer therapy mediators. They can act as nanocarriers of anticancer drugs and generate localized heat when exposed to an alternating magnetic field (AMF), resulting in combined effects of chemotherapy and magnetic hyperthermia therapy. Thus, we designed and synthesized novel MIONs directly through a co-precipitation method by a single step one-pot aqueous green process using carboxymethylcellulose (CMC) as a multifunctional, biocompatible and water-soluble biopolymer ligand (iron oxide nanoparticle-CMC, MION@CMC). They were bioconjugated via amide bonds with doxorubicin (DOX, an anticancer drug) forming nanohybrids (MION@CMC-DOX). The CMC, MION@CMC and MION@CMC-DOX nanoconjugates were comprehensively characterized by 1HNMR, FTIR, TEM/SAED/EDX, UV-visible, XRD, zeta potential (ZP) and DLS analyses. Moreover, cytotoxicity and cell killing activities of these nanoconjugates were assessed by in vitro biological assays. The nanoconjugates were incubated with glioma cells (U87), a magnetic hyperthermia (MHT) assay was performed for evaluating the activity against brain cancer cells and confocal laser scanning laser microscopy was used for bioimaging their cellular uptake pathways. The results showed that fairly monodisperse and water-soluble ultra-small iron oxide nanoparticles (Fe3O4) were synthesized (core size = 7 ± 2 nm) and stabilized by CMC producing negatively charged nanocolloids (-38 ± 3 mV, MION@CMC; hydrodynamic radius, HD = 38 ± 2 nm). The results confirmed the conjugation of MION@CMC with DOX by amide bonds, leading to the development of magnetopolymersome nanostructures (MION@CMC-DOX). The cell viability bioassays evidenced low toxicity of MION@CMC compared to the severe cytotoxicity of MION@CMC-DOX nanosystems mainly caused by the release of DOX. Under an alternating magnetic field, MION@CMC and MION@CMC-DOX systems demonstrated activity for killing U87 cancer cells due to the heat generated by hyperthermia. In addition, the MION@CMC-DOX bioconjugates showed significantly higher cell killing response when exposed to an AMF due to the combined chemotherapy effect of DOX release inside the cancer cells triggering apoptotic pathways.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30869664     DOI: 10.1039/c8bm01528g

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  10 in total

Review 1.  Hyperthermia treatment advances for brain tumors.

Authors:  Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis
Journal:  Int J Hyperthermia       Date:  2020-07       Impact factor: 3.914

2.  pH-Responsive Carboxymethylcellulose Nanoparticles for 68Ga-WBC Labeling in PET Imaging.

Authors:  Anna Maria Piras; Angela Fabiano; Stefania Sartini; Ylenia Zambito; Simona Braccini; Federica Chiellini; Angela G Cataldi; Francesco Bartoli; Ana de la Fuente; Paola Anna Erba
Journal:  Polymers (Basel)       Date:  2019-10-05       Impact factor: 4.329

3.  Polyethylene Glycol Coated Magnetic Nanoparticles: Hybrid Nanofluid Formulation, Properties and Drug Delivery Prospects.

Authors:  Rashmi Mannu; Vaithinathan Karthikeyan; Nandakumar Velu; Chandravadhana Arumugam; Vellaisamy A L Roy; Anantha-Iyengar Gopalan; Gopalan Saianand; Prashant Sonar; Kwang-Pill Lee; Wha-Jung Kim; Dong-Eun Lee; Venkatramanan Kannan
Journal:  Nanomaterials (Basel)       Date:  2021-02-09       Impact factor: 5.076

Review 4.  Polymer-Based Hybrid Nanoarchitectures for Cancer Therapy Applications.

Authors:  Arun Kumar; Mirkomil Sharipov; Abbaskhan Turaev; Shavkatjon Azizov; Ismatdjan Azizov; Edwin Makhado; Abbas Rahdar; Deepak Kumar; Sadanand Pandey
Journal:  Polymers (Basel)       Date:  2022-07-26       Impact factor: 4.967

Review 5.  Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.

Authors:  Agata M Gawel; Ravi Singh; Waldemar Debinski
Journal:  Biomedicines       Date:  2022-07-05

6.  Tunable magnetothermal properties of cobalt-doped magnetite-carboxymethylcellulose ferrofluids: smart nanoplatforms for potential magnetic hyperthermia applications in cancer therapy.

Authors:  Alice G Leonel; Alexandra A P Mansur; Sandhra M Carvalho; Luis Eugenio F Outon; José Domingos Ardisson; Klaus Krambrock; Herman S Mansur
Journal:  Nanoscale Adv       Date:  2021-01-04

Review 7.  Physically stimulus-responsive nanoparticles for therapy and diagnosis.

Authors:  Fatemeh Farjadian; Soheila Ghasemi; Mohsen Akbarian; Mojtaba Hoseini-Ghahfarokhi; Mohsen Moghoofei; Mohammad Doroudian
Journal:  Front Chem       Date:  2022-09-14       Impact factor: 5.545

8.  In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment.

Authors:  Chang-Seuk Lee; Tae Wan Kim; Da Eun Oh; Su Ok Bae; Jaesung Ryu; Hyejeong Kong; Hyeji Jeon; Hee Kyung Seo; Seob Jeon; Tae Hyun Kim
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

9.  Preparation and Characterization of Fe3O4@MTX Magnetic Nanoparticles for Thermochemotherapy of Primary Central Nervous System Lymphoma in vitro and in vivo.

Authors:  Xinyu Dai; Jingqing Yao; Yuejiao Zhong; Yuntao Li; Qianling Lu; Yan Zhang; Xue Tian; Zhirui Guo; Tingting Bai
Journal:  Int J Nanomedicine       Date:  2019-12-05

Review 10.  Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management.

Authors:  Lavinia Salama; Elizabeth R Pastor; Tyler Stone; Shaker A Mousa
Journal:  Biomedicines       Date:  2020-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.